ENVALITH
キッセイ薬品工業株式会社 logo

KISSEI PHARMACEUTICAL CO., LTD.

4547・Prime Market・Pharmaceuticals

キッセイ薬品工業株式会社 logo
KISSEI PHARMACEUTICAL CO., LTD.4547

Pharmaceuticals Business

Kissei Pharmaceutical's core segment. A drug discovery-driven pharmaceuticals business developing in-house and in-licensed products both domestically and overseas.

PeriodCurrentPreviousChange
Segment net sales (external customers)¥77,950 million¥75,299 million↑
Segment operating income (loss)△¥4,524 million¥4,684 million↓
Segment assets¥256,455 million¥229,310 million↑
Depreciation and amortization¥4,206 million¥4,129 million↑
Increase in property, plant and equipment and intangible assets¥6,161 million¥8,086 million↓
Domestic pharmaceutical sales¥67,764 million¥63,975 million↑
Export and overseas licensing revenue¥6,691 million¥7,770 million↓
Rare disease drug sales¥15,377 million¥11,283 million↑
Renal/dialysis drug sales¥17,255 million¥15,617 million↑
Urology drug sales¥22,332 million¥23,384 million↓

Business Details

Centered on the manufacture and sale of prescription pharmaceuticals, with additional purchase and sale of healthcare foods. Domestically, the segment focuses on the urology, renal/dialysis, and rare disease fields, with pharmaceutical wholesalers such as Alfresa and S.M.D. as principal sales channels. Overseas, the segment pursues a licensing-out strategy centered on Yselty (Linzagolix). The segment accounted for 80.0% of consolidated net sales in FY2026 (ending March 2026), remaining the core business, but the Pharmaceuticals segment fell into an operating loss due to increased R&D expenses.

Recent Overview

Sales increased but the segment fell into an operating loss due to higher R&D expenses, while regulatory risk regarding Tavneos materialized.

Pharmaceuticals segment net sales for FY2026 (ending March 2026) rose 3.5% year on year to ¥77,950 million. Rare disease drugs drove growth, reaching ¥15,377 million (up 36.3% year on year), but an increase in selling, general and administrative expenses—primarily R&D expenses—caused the segment to fall into an operating loss of ¥4,524 million (versus operating income of ¥4,684 million in the prior period). In addition, a major risk event occurred regarding Tavneos: the FDA proposed withdrawal of U.S. approval, and the EMA also initiated a review over data integrity concerns. Meanwhile, the licensing strategy continued to advance, with Yselty newly launched domestically and in Taiwan, and a sublicensing agreement for Olutasidenib concluded in Taiwan (subsequent event).

Key Products

product
Beova Tablets (Vibegron)

Core product in the urology drug category. It continued to contribute to sales growth during the period, but the urology drug category overall came to ¥22,332 million (down 4.5% year on year), affected by drug price revisions and other factors.

product
Tavneos Capsules (Avacopan)

Contributed to growth in sales of rare disease drugs. However, a major risk event has occurred: the FDA proposed withdrawal of U.S. approval on April 27, 2026, and the EMA also initiated a review on January 30, 2026, over concerns regarding the integrity of data from the international joint Phase III clinical trial.

product
Korsuva IV Syringe for Dialysis (Difelikefalin)

Contributed to growth in the renal/dialysis drug category. This category maintained solid growth, reaching ¥17,255 million (up 10.5% year on year).

product
Tavalisse Tablets (Fostamatinib)

Drove growth in the rare disease drug category. In July 2025, JW Pharmaceutical, the sublicensee in South Korea, newly launched the product in South Korea.

product
Yselty (Linzagolix)

Newly launched domestically in March 2026 for the indication of uterine fibroids. In Taiwan, Sinphar Pharmaceutical newly launched the product in March 2026. In October 2025, exclusive development and marketing rights in Canada were licensed to Searchlight Pharma (Canada). In Europe, Theramex continues to launch and prepare for launch in various countries.

product
Olutasidenib (in development)

Currently in preparation for domestic approval application. In May 2026, sublicensed development and marketing rights in Taiwan to Orient Europharma (Taiwan) (subsequent event). The company expects to receive an upfront payment, milestone payments, and to supply formulations under the agreement.

product
Matsupexole (KDT-3594)

In March 2026, the domestic late-stage Phase II clinical trial was unblinded and achieved its primary endpoint. This in-house developed product's future development progress is drawing attention.

product
Veligrotug / Elegrobart (VRDN-003)

An in-licensed product for which an agreement to acquire exclusive development and marketing rights in Japan was concluded with Viridian Therapeutics (U.S.) in July 2025.

Growth Drivers

  • Continued growth in rare disease drugs (Tavneos, Korsuva, Tavalisse) (¥15,377 million in FY2026 (ending March 2026), up 36.3% year on year)
  • Domestic new launch of Yselty (Linzagolix) (March 2026) and expanded licensing-out to Taiwan and Canada
  • Solid growth in renal/dialysis drugs (¥17,255 million, up 10.5% year on year)
  • Progress in preparations for domestic approval application of Olutasidenib and monetization through the Taiwan sublicensing agreement
  • Development progress for Matsupexole (KDT-3594) following achievement of the primary endpoint in the late-stage Phase II clinical trial
  • Expansion of the in-house drug discovery pipeline with the start of domestic Phase I clinical trials for KSP-0914, KSP-0576, and KSP-0930
  • Strengthened open innovation through the establishment of the Boston Open Innovation Office

Risks

  • Significant risk to the rare disease business from the FDA's proposed withdrawal of U.S. approval for Tavneos (announced April 27, 2026) and the EMA's initiation of a data integrity review
  • Risk of continued operating losses due to increased selling, general and administrative expenses, primarily R&D expenses (segment operating loss of ¥4,524 million in FY2026 (ending March 2026))
  • Profit pressure from ongoing drug price containment policies, including drug price revisions (interim revision in April 2025, revision in April 2026)
  • Decline in export and overseas licensing revenue (¥6,691 million, down 13.9% year on year) and associated volatility risk (uncertainty over milestone and running royalty payments)
  • Drug price revisions and competitive pressure affecting existing products, including a decline in urology drug sales (¥22,332 million, down 4.5% year on year)
  • Risk of increased costs associated with large-scale in-licensing (in-licensing costs for products such as Veligrotug / Elegrobart)
  • Profit pressure from a rising trend in the cost of sales ratio

Information Services Business

An IT services business encompassing system integration, medical systems, and related offerings operated by Kissei Comtec.

PeriodCurrentPreviousChange
Segment net sales (revenue from contracts with customers)¥17,225 million¥11,395 million↑
Sales to external customers¥14,237 million¥8,735 million↑
Segment profit¥1,102 million¥636 million↑
Segment assets¥15,171 million¥10,648 million↑
Depreciation and amortization¥603 million¥610 million—
Inter-segment internal sales¥2,987 million¥2,660 million↑

Business Details

Consolidated subsidiary Kissei Comtec Co., Ltd. operates in three business areas: System Integration Services, System Resource Services (rental of information-related equipment, network construction, etc.), and Medical System Development & Sales. The segment also has a certain scale of internal sales within the group (inter-segment transactions), with sales to external customers reaching ¥14,237 million for the current consolidated fiscal year. Sales increased significantly due to the receipt of large-scale orders related to the GIGA School policy promoted by the Ministry of Education, Culture, Sports, Science and Technology.

Recent Overview

Sales to external customers rose sharply, up 63.0% year on year, driven by orders related to the GIGA School policy.

In FY2026 (ending March 2026), sales to external customers rose sharply to ¥14,237 million (up 63.0% year on year), driven by the receipt of orders related to the GIGA School policy promoted by the Ministry of Education, Culture, Sports, Science and Technology. Segment profit also improved substantially, reaching ¥1,102 million (up 73.3% year on year). However, in the consolidated earnings forecast for FY2027 (ending March 2027), a decline in sales is expected in the Information Services business due to the reversal of the current period's significant sales increase.

Key Products

service
System Integration Services

Provides system construction, implementation, and operational support for corporations, government agencies, and educational institutions. During the period, orders related to the GIGA School policy contributed significantly to the substantial increase in sales.

service
System Resource Services

Provides IT infrastructure services including rental and leasing of information-related equipment and network construction and maintenance. Includes demand from within the group.

product
Medical System Development & Sales

Develops, sells, and maintains medical information systems in response to digitalization and DX promotion needs in the medical field. Captures demand for digitization among medical institutions.

Growth Drivers

  • Continued solid ICT demand and capital investment appetite among corporations and educational institutions
  • IT investment demand from government agencies and educational institutions related to policies such as the GIGA School initiative
  • Demand for internal group IT services (inter-segment sales of ¥2,987 million)
  • Response to digitalization and DX promotion needs in the medical field

Risks

  • Risk of decreased sales in the next fiscal year due to the reversal of GIGA School policy-related orders
  • Uncertain business sentiment amid weak personal consumption caused by yen depreciation and rising prices
  • Intensifying price competition amid a challenging competitive environment
  • Risk of sales volatility due to dependence on large-scale projects

Construction & Facility Maintenance Business

A general construction services business operated by Hashiba Technos, covering everything from building construction to facility maintenance.

PeriodCurrentPreviousChange
Segment net sales (revenue from contracts with customers)¥7,381 million¥5,985 million↑
Sales to external customers¥4,331 million¥3,435 million↑
Inter-segment internal sales¥3,049 million¥2,550 million↑
Segment operating income¥595 million¥460 million↑
Segment assets¥4,866 million¥4,358 million↑
Depreciation and amortization¥25 million¥23 million↑
Increase in property, plant and equipment and intangible assets¥31 million¥31 million—

Business Details

Consolidated subsidiary Hashiba Technos Co., Ltd. operates a General Construction Services business, handling everything from building construction to the maintenance and management of facilities and equipment on an integrated basis. It has an order-based business model that includes sales within the group, with inter-segment internal sales exceeding external sales. For the current consolidated fiscal year (FY2026 ending March 2026), sales to external customers were ¥4,331 million, and inter-segment internal sales were ¥3,049 million. Orders expanded on the back of solid ICT demand and capital investment appetite, achieving a substantial 26.1% year-on-year increase in sales.

Recent Overview

Sales to external customers rose sharply by 26.1%, with operating income also expanding to ¥595 million.

In the Construction & Facility Maintenance business for FY2026 (ending March 2026), sales to external customers achieved a substantial increase of 26.1% year on year to ¥4,331 million. Inter-segment internal sales also expanded to ¥3,049 million (up 19.6% year on year), bringing total revenue from contracts with customers to ¥7,381 million. Operating income increased to ¥595 million (versus ¥460 million in the prior period). In addition to solid ICT demand and capital investment appetite, easing concerns over U.S. tariff policy led to a gradual recovery in business sentiment, expanding orders.

Key Products

service
General Construction Services

Handles everything from new construction and renovation work on buildings to the maintenance, management, and upkeep of facilities and equipment on an integrated basis. Adopts an order-based business model providing services to both internal group parties (such as construction of manufacturing facilities for Kissei Pharmaceutical) and external customers.

Growth Drivers

  • Expanding orders driven by continued solid ICT demand and capital investment appetite
  • Increased demand from within the group (such as construction of manufacturing facilities for Kissei Pharmaceutical) (internal sales of ¥3,049 million, up 19.6% year on year)
  • Expansion of sales to external customers (¥4,331 million in FY2026 (ending March 2026), up 26.1% year on year)
  • Sustained private-sector capital investment amid a gradual recovery in business sentiment

Risks

  • Risk of rising construction material costs due to yen depreciation and price increases
  • Risk of profit pressure from labor shortages and rising labor costs
  • Risk of a slowdown in private-sector capital investment due to a lack of robust domestic demand or destabilizing international conditions
  • Risk of performance being tied to the parent company's trends due to a structure dependent on internal group sales (internal sales exceeding external sales)

Merchandise Sales Business

A small, diversified merchandise sales segment that plays a complementary role within the group (0.9% of consolidated net sales to external customers).

PeriodCurrentPreviousChange
Revenue from contracts with customers (segment total)¥1,137 million¥1,068 million↑
Sales to external customers¥886 million¥860 million↑
Inter-segment internal sales¥251 million¥207 million↑
Segment profit¥136 million¥99 million↑
Segment assets¥2,397 million¥2,648 million↓
Depreciation and amortization¥34 million¥33 million—
Share of consolidated net sales (external customers)0.9%1.0%—

Business Details

A segment operated by consolidated subsidiaries. Its main business is the development, production, and sale of noodles centered on Shinshu Soba, alongside the sale of various equipment, vehicles, and fuel, as well as an insurance agency business. Its position within the group is complementary, with revenue from contracts with customers totaling ¥1,137 million, comprising sales to external customers of ¥886 million and inter-segment internal sales of ¥251 million. Business operations continue in a challenging competitive environment amid weak personal consumption.

Recent Overview

Both sales to external customers and segment profit increased modestly, while assets contracted.

In the Merchandise Sales business for FY2026 (ending March 2026), sales to external customers rose to ¥886 million (up 2.9% year on year), and segment profit increased to ¥136 million (up 37.4% year on year), achieving higher sales and profit. Inter-segment internal sales also expanded to ¥251 million (from ¥207 million in the prior period). On the other hand, segment assets contracted to ¥2,397 million from ¥2,648 million in the prior period. Modest profit improvement was achieved even amid an environment of price increases and weak personal consumption.

Key Products

product
Noodles centered on Shinshu Soba

Develops, produces, and sells noodles centered on Shinshu Soba. Business operations continue in a challenging competitive environment amid weak personal consumption, and rising raw material costs due to price increases are affecting profitability.

product
Equipment, Vehicle & Fuel Sales

Sells various equipment, vehicles, and fuel. Continued capital investment appetite serves as a supporting factor, but the trend of shrinking merchandise procurement continues.

service
Insurance Agency Business

Operates an insurance agency business serving customers both within and outside the group. The overall sales scale of the segment is small, and internal group transactions (inter-segment internal sales of ¥251 million) also contribute to a certain extent.

Growth Drivers

  • Continued production and sale of noodles centered on Shinshu Soba (external sales up 2.9% year on year)
  • Expansion of inter-segment internal sales (from ¥207 million in the prior period to ¥251 million in the current period)
  • Support for equipment sales from continued capital investment appetite
  • Improvement in segment profit margin (from ¥99 million in the prior period to ¥136 million in the current period, up 37.4% year on year)

Risks

  • Continuation of a challenging competitive environment amid weak personal consumption
  • Risk of rising raw material costs due to yen depreciation and price increases
  • Small share of approximately 0.9% of overall group sales, resulting in lower priority for resource allocation
  • Risk of deteriorating demand conditions due to destabilizing international conditions

Last updated: July 17, 2026